Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFINITY study of imeglimin effects on hemoglobin, erythrocytes, and glycemic markers in type 2 diabetes
jRCTs031220489Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imeglimin in type 2 diabetes mellitus (T2DM), sponsored by Sumitomo Pharma. Primary endpoint: Change in hemoglobin concentration from baseline to month 6 of imeglimin administration. Started Feb 2023; status: recruiting.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031220489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220489.